Application 215701
- Type
- ANDA
- Sponsor
- SHANDONG
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | SUGAMMADEX SODIUM | SUGAMMADEX SODIUM | INJECTABLE;INJECTION | 200MG/2ML(100MG/ML) | No | No |
| 002 | SUGAMMADEX SODIUM | SUGAMMADEX SODIUM | INJECTABLE;INJECTION | 500MG/5ML(100MG/ML) | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A215701-001 | SUGAMMADEX SODIUM | SUGAMMADEX SODIUM | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-10-06 | |
| A215701-002 | SUGAMMADEX SODIUM | SUGAMMADEX SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-10-06 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A215701-001 | AP |
| A215701-002 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A215701-001 | SUGAMMADEX SODIUM | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-10-06 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A215701-002 | SUGAMMADEX SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-10-06 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A215701-001 | SUGAMMADEX SODIUM | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-10-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A215701-002 | SUGAMMADEX SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-10-06 | c2088c7a36db… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A215701-001 | AP | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A215701-002 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A215701-001 | AP | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A215701-002 | AP | 1 | c2088c7a36db… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sugammadex | SUGAMMADEX SODIUM | Mullan Pharmaceutical Inc. | 5373abf1-c6ef-4295-9b2e-b07964b2fe37 | 2026-11-02 | Warnings, Adverse reactions | 215701 ANDA215701 |
| Sugammadex | SUGAMMADEX | Shandong New Time Pharmaceutical Co., Ltd. | 56400560-a2df-4126-b424-9e4b91e53a8b | 2025-03-24 | Warnings, Adverse reactions | 215701 ANDA215701 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.